Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp ASCO20 Conference Call Transcript

May 29, 2020 / 12:30PM GMT
Release Date Price: $65.14 (-2.76%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines Conference Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Kristin Hodous of Blueprint Medicines. Please go ahead.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone, and thank you for joining us today to review the updated clinical data for pralsetinib and RET fusion-positive lung and thyroid which we announced this morning as part of the American Society of Clinical Oncology 2020 Virtual Scientific Program. You can access the press release for the data as well slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

With me today with prepared remarks are Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; and Christy Rossi, our Chief Commercial Officer.

Before we get started,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot